---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-276007"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:09:59.713121+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Viridian Q3 net loss $47.7M; new CEO Mahoney; cash runway into 2026 after $185M placement

## Summary
- Net loss $47.7M vs $28.9M YoY; R&D $30.4M (+$8.3M) and G&A $20.9M (+$12.0M).
- Cash, equivalents & ST investments $313M at Sep 30; closed $185M private placement Nov 1 extending runway into 2026.
- Stephen Mahoney appointed President/CEO in Oct; new COO Thomas Beetham and CBO Shan Wu also hired.
- THRIVE (active TED) and THRIVE-2 (chronic) Phase 3 trials on track; topline mid-2024 and year-end 2024 respectively.
- Subcutaneous program selection by year-end 2023; Phase 1 data for VRDN-001/002/003 expected Q4 2023.

## SEC filing metadata
- accession: 0001193125-23-276007
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312523276007/0001193125-23-276007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312523276007/d85328d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-276007
- JSON: https://secwatch.observer/filing/0001193125-23-276007.json
- Plain text: https://secwatch.observer/filing/0001193125-23-276007.txt

## Key facts
- Earnings Releases
  Viridian Therapeutics, Inc.\DE reported financial results for the third quarter ended September 30, 2023.
  - Period: the third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 13, 2023, Viridian Therapeutics, Inc. (the “Company”), issued a press release reporting financial results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590750/000119312523276007/0001193125-23-276007-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.